IXICO plc announced that an existing client has contracted IXICO to provide imaging services for the extension study of their Huntington's disease ('HD') Ph2b trial. This is a new study protocol and results in a new work order worth just under £2 million which IXICO expects to deliver over the next 4 years.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
7.25 GBX | +1.75% | -1.69% | -42.00% |
May. 21 | EARNINGS AND TRADING: Topps Tiles in strategic shift as swings to loss | AN |
May. 21 | Earnings Flash (IXI.L) IXICO Posts Fiscal H1 Revenue GBP2.5M | MT |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-42.00% | 4.38M | |
+64.23% | 55.07B | |
-2.31% | 41.79B | |
+44.36% | 40.22B | |
-8.29% | 28.17B | |
+11.97% | 26.28B | |
-21.16% | 18.93B | |
+7.54% | 13.03B | |
+27.17% | 12.26B | |
+25.72% | 12.21B |
- Stock Market
- Equities
- IXI Stock
- News IXICO plc
- IXICO plc Announces Contract Win in Huntington's Disease